STATs in cancer, inflammation and immunity: A leading role of STAT3

Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA.
Nature Reviews Cancer (Impact Factor: 37.4). 11/2009; 9(11):798-809. DOI: 10.1038/nrc2734
Source: PubMed


Commensurate with their roles in regulating cytokine-dependent inflammation and immunity, signal transducer and activator of transcription (STAT) proteins are central in determining whether immune responses in the tumour microenvironment promote or inhibit cancer. Persistently activated STAT3 and, to some extent, STAT5 increase tumour cell proliferation, survival and invasion while suppressing anti-tumour immunity. The persistent activation of STAT3 also mediates tumour-promoting inflammation. STAT3 has this dual role in tumour inflammation and immunity by promoting pro-oncogenic inflammatory pathways, including nuclear factor-kappaB (NF-kappaB) and interleukin-6 (IL-6)-GP130-Janus kinase (JAK) pathways, and by opposing STAT1- and NF-kappaB-mediated T helper 1 anti-tumour immune responses. Consequently, STAT3 is a promising target to redirect inflammation for cancer therapy.

Download full-text


Available from: Hua Yu, May 15, 2014
  • Source
    • "Treatment of Spry124 À/À MEFs with a MEK inhibitor, PD0325901 (Barrett et al., 2008), led to a dose-dependent reduction in Erk activation, and reduced baseline expression of five out of seven Spry124 À/À target genes tested to Spry124 fl/fl levels, indicating their dependence on Erk signaling (Figures 1E and S1F). We also noted that a number of Spry124 À/À targets, including Ccl2 and Fgf2, are Stat3 target genes (Yu et al., 2009), suggesting that Stat3, an oncogenic TF activated by RTK signaling, may be aberrantly activated upon Spry loss. Accordingly, Spry124 À/À MEFs displayed elevated constitutive phosphorylation of Stat3 tyrosine 705 and enhanced FGFinduced phosphorylation of Stat3 serine 727 (Figure S1G). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Unrestrained receptor tyrosine kinase (RTK) signaling and epigenetic deregulation are root causes of tumorigenesis. We establish linkage between these processes by demonstrating that aberrant RTK signaling unleashed by oncogenic HRas(G12V) or loss of negative feedback through Sprouty gene deletion remodels histone modifications associated with active typical and super-enhancers. However, although both lesions disrupt the Ras-Erk axis, the expression programs, enhancer signatures, and transcription factor networks modulated upon HRas(G12V) transformation or Sprouty deletion are largely distinct. Oncogenic HRas(G12V) elevates histone 3 lysine 27 acetylation (H3K27ac) levels at enhancers near the transcription factor Gata4 and the kinase Prkcb, as well as their expression levels. We show that Gata4 is necessary for the aberrant gene expression and H3K27ac marking at enhancers, and Prkcb is required for the oncogenic effects of HRas(G12V)-driven cells. Taken together, our findings demonstrate that dynamic reprogramming of the cellular enhancer landscape is a major effect of oncogenic RTK signaling. Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
    Cell Reports 08/2015; 12(8). DOI:10.1016/j.celrep.2015.06.078 · 8.36 Impact Factor
  • Source
    • "In addition, the inhibition of JAK–STAT signaling by 4-AAQB (Fig. 5) was of no lesser relevance since several studies have demonstrated that STATs, specifically STAT3, is essential for various aspects of tumor formation, including proliferation, angiogenesis, metastasis, apoptosis, determination of its terminal fate, immune cell mobilization, and invariably , chemosensitivity (Jove, 2000; Levy and Inghirami, 2006; Yu et al., 2009). Associated with dysregulation of these signaling pathways was the inactivation or down-regulation of their downstream target genes or transcriptional factors, such as vimentin, β-catenin, Nanog, and Sox-2, in a dose-dependent manner. "
    [Show abstract] [Hide abstract]
    ABSTRACT: 4-Acetylantroquinonol B (4-AAQB), closely related to the better known antroquinonol, is a bioactive isolate of the mycelia of Antrodia camphorata, a Taiwanese mushroom with documented anti-inflammatory, hypoglycaemic, vasorelaxative, and recently demonstrated, antiproliferative activity. Based on its traditional use, we hypothesized that 4-AAQB may play an active role in the suppression of cellular transformation, tumor aggression and progression, as well as chemoresistance in colorectal carcinoma (CRC). In this study, we investigated the antiproliferative role of 4-AAQB and its underlying molecular mechanism. We also compared its anticancer therapeutic potential with that of antroquinonol and the CRC combination chemotherapy of choice - Folinic acid, Fluorouracil and Oxaliplatin (FOLFOX). Our results showed that 4-AAQB was most effective in inhibiting tumor proliferation, suppressing tumor growth and attenuating stemness-related chemoresistance. 4-AAQB negatively regulates vital oncogenic and stem cell maintenance signal transduction pathways, including the Lgr5/Wnt/β-catenin, JAK-STAT, and non-transmembrane receptor tyrosine kinase signaling pathways, as well as inducing a dose-dependent downregulation of ALDH and other stemness related factors. These results were validated in vivo; with animal studies showing 4-AAQB possessed comparable tumor-shrinking ability as FOLFOX and potentiates ability of the later to reduce tumor size. Thus, 4-AAQB, a novel small molecule, projects as a potent therapeutic agent for monotherapy or as a component of standard combination chemotherapy. Copyright © 2015. Published by Elsevier Inc.
    Toxicology and Applied Pharmacology 07/2015; 288(2). DOI:10.1016/j.taap.2015.07.025 · 3.71 Impact Factor
  • Source
    • "Signal transducer and activator of transcription (STAT) proteins are inflammatory mediators which transduce signal across the cytoplasm and function as transcription factors in the nucleus (Yu et al., 2009). Activations of the STAT proteins through growth factors and cytokine receptors have been implicated in initiation and progression of cancer (Yu and Jove, 2004; Yu et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The single nucleotide polymorphism (SNP) rs1053004 in Signal transducer and activator of transcription 3 (STAT3) was recently reported to be associated with chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) in a Chinese cohort. This study was aimed at investigating whether the SNP might also contribute to HCC susceptibility in the Thai population. Study subjects were enrolled and divided into 3 groups including CHB-related HCC (n=211), CHB without HCC (n=233) and healthy controls (n=206). The SNP was genotyped using allelic discrimination assays based on TaqMan real-time PCR. Data analysis revealed that the distribution of different genotypes was in Hardy-Weinberg equilibrium (P>0.05). The frequencies of allele T (major allele) in HCC patients, CHB patients and healthy controls were 51.4%, 58.6% and 61.4%, respectively, whereas the frequencies of C allele (minor allele) were 48.6%, 41.4% and 38.6%. The C allele frequency was higher in HCC when compared with CHB patients (odds ratio (OR)=1.34, 95% confidence interval (CI)=1.02-1.74, P=0.032). The genotype of SNP rs1053004 (CC versus TT+TC) was significantly associated with an increased risk when compared with CHB patients (OR=1.83, 95% CI=1.13-2.99, P=0.015). In addition, we observed a similar trend of association when comparing HCC patients with healthy controls (OR=1.77, 95% CI=1.07-2.93, P=0.025) and all controls (OR=1.81, 95% CI=1.19-2.74, P=0.005). These findings suggest that the SNP rs1053004 in STAT3 might contribute to HCC susceptibility and could be used as a genetic marker for HCC in the Thai population.
    Asian Pacific journal of cancer prevention: APJCP 07/2015; 16(12):5069-5073. DOI:10.7314/APJCP.2015.16.12.5069 · 2.51 Impact Factor
Show more